Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
The influence of steroidotherapy in COPD exacerbation on matrix metalloproteinase MMP-9 level in BAL, induced sputum and serum Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004
Matrix metalloproteinase levels of bronchial mucosa and the correlation with clinical parameters in clinically stable bronchiectasis Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Elevated BALF PEDF levels are related to disease severity, inflammation and small airway obstruction in COPD patientes Source: International Congress 2017 – COPD biomarkers Year: 2017
Relationship between MMP-9 and TIMP-1 induced sputum concentration and the stage of chronic obstructive pulmonary disease‘s (COPD) Source: Annual Congress 2008 - Issues in the management of COPD in the community Year: 2008
MMP2, 8, 9 and TIMP1-4 levels in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease and bronchial asthma Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010
Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Human macrophage elastase (MMP-12) expression in human emphysematous lungs: role in extracellular matrix remodelling in chronic obstructive pulmonary diseases (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
The expression of MMP2, 9 and TIMP1 mRNA in bronchoalveolar cells of patients with chronic obstructive pulmonary disease (COPD) and bronchial asthma Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases Year: 2009
COPD is associated with reduced pulmonary interstitial expression of pentraxin-3 Source: Eur Respir J 2012; 39: 830-838 Year: 2012
Relationship between Candida strains colonization and MMP-9 and TIMP-1 induced sputum concentration in chronic obstructive pulmonary disease‘s (COPD) patients and healthy control group Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010
Imbalance between serum matrix metalloproteinase-9 and its inhibitor is associated with increased airway wall thickness in uncontrolled asthmatics Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation Year: 2010
Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001
Matrix metalloproteinases and lung disease severity in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001
Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013
Osteopontin expression and relation to disease severity in human asthma Source: Eur Respir J 2011; 37: 331 Year: 2011